EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Bio Roundup: Obamacare Persists, FDA Approves, Vertex Wows & More

(Page 2 of 2)

say whether the comprehensive workup, including DNA sequencing, blood and stool analysis, and FitBit tracking, made people healthier.

MONEY IN, MONEY OUT

—Bicoastal venture firm Clarus announced a new $910 million fund, its fourth. The fund will focus on later-stage products already in clinical study and on what it called “structured financing” deals.

—The venture arms of international drug giants Novartis (NYSE: NVS) and Sanofi (NYSE: SNY) co-led a $14 million Series A investment in NeuroVia, of Cambridge, MA, which has a drug to treat the rare metabolic disorder cerebral adrenoleukodystrophy.

—New Haven, CT-based Trevi Therapeutics raised a $50.5 million Series C round of financing as it prepares Phase 3 tests of its anti-itching drug.

—Kala Pharmaceuticals (NASDAQ: KALA) of Waltham, MA, raised $90 million in an IPO, selling 6 million shares at $15 apiece. The maker of eye treatments plans to ask the FDA by year’s end to review its lead drug for approval.

—Too late for last week’s roundup: Akcea Therapeutics (NASDAQ: AKCA) raised $125 million in its IPO, but the Cambridge biotech had to price its shares well below the planned range.

Image of U.S. map by Dave Winer via a Creative Commons 2.0 license.

Single PageCurrently on Page: 1 2 previous page